Trade secrets: an alternative for life sciences IP?

Over the past decade, three high-profile US Supreme Court decisions—known by their shorthand names as Alice, Mayo, and Myriad—have generated significant uncertainty over what is and isn’t patentable.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

Careers

New UK High Court judge named as replacement for Justice Meade

23 September 2026 Following the prominent patent judge’s promotion to the Court of Appeal, the judiciary has appointed a King’s Counsel with 35 years’ experience as a barrister.

More features

New UK High Court judge named as replacement for Justice Meade

US firm hires litigation pro whose clients include Pfizer, Medtronic

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Beyond the primary patent: How pharma can build competitive barriers

Patent lawyers and judges discuss lofty UPC issues in grand London venue

10x Genomics wins latest round in Parse patent dispute

Trade secrets: an alternative for life sciences IP?

More on this story

Editor's picks

Editor's picks

More features